AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. **(Currently Amended)** A method for the treatment or inhibition of hypercholesterolemia or hypertriglyceridemia in an affected patient, comprising the step of:

administering to the patient a composition comprising a therapeutically-effective amount of a compound of either Formula I:

a) Formula I



wherein R and R_1 are independently selected from the group consisting of H, lower alkoxy (C_{1-6}), or lower alkyl (C_{1-6}); R_2 is selected from the group consisting of aryl (C_{6-12}) and substituted aryl; M is hydrogen, sodium, potassium, ammonium, diethanolamine, cyclohexylamine, a naturally-occurring amino acid of MW less than 500 kD, lower alkyl (C_{1-6}), cycloalkyl, or aryl (C_{6-12}); and n is 0-5; or

b) Formula III:

Formula III



wherein R and R_1 are independently selected from the group consisting of H, lower alkoxy (C_{1-6}), or lower alkyl (C_{1-6}); R_2 is selected from the group consisting of aryl (C_{6-12}) and substituted aryl; M is hydrogen, sodium, potassium, ammonium, diethanolamine, cyclohexylamine, a naturally-occurring amino acid of MW less than 500 kD, lower alkyl (C_{1-6}), cycloalkyl, or aryl (C_{6-12}); and n is 0-5; or

c) ~~Formula IV:~~

~~Formula IV~~



~~wherein R and R1 are independently selected from the group consisting of H, lower alkoxy (C1-6), or lower alkyl (C1-6); R2 is selected from the group consisting of aryl (C6-12) and substituted aryl; M is hydrogen, sodium, potassium, ammonium, diethanolamine, cyclohexylamine, a naturally-occurring amino acid of MW less than 500 kD, lower alkyl (C1-6), cycloalkyl, or aryl (C6-12); and n is 0-5; or,~~

~~d)~~ any combination thereof.

2. (Original) The method of claim 1, wherein in said composition M is hydrogen, potassium or sodium; n is 0-2; R and R_1 are independently selected from the group consisting of H and C_3H_7; R_1 is selected from the group consisting of H, CH_3, CH_3-O-, C_2H_5, and C_3H_7; and R_2 is an aryl (C_{6-12}) or a substituted aryl selected from the group consisting of Formula II:

Formula II



,


,



, wherein X is a halogen, lower alkyl (C_{1-6}), lower alkoxy (C_{1-6}), cycloalkyl, cycloalkoxy, aryl (C_{6-12}), substituted aryl or hydroxy and n is 0, 1, 2, 3, or 4.

3. (Original) The method of claim 2, wherein said therapeutically-effective amount is from 20 mg/kg/day to 2500 mg/kg/day.

4. (Original) The method of claim 1, wherein said composition further comprises at least one pharmaceutically-acceptable carrier, diluent, or excipient.

5. to 7. (Cancelled)

8. (Original) The method of claim 2, wherein said composition further comprises at least one pharmaceutically-active carrier, diluent, or excipient.

9. to 15. (Cancelled)

16. **(Currently Amended)** The method of claim 2, wherein said composition comprises an effective amount of ~~[phenylbutyric acid,]~~ phenylbutylglutamine~~[,]~~ or isophenylbutylglutamine or pharmaceutically acceptable salts thereof.

17. and 18. (Cancelled)

19. **(Currently Amended)** The method of claim 1, wherein the compound of Formula I is the sodium salt of phenylacetylglutamine~~[,]~~ and the compound of Formula III is the sodium salt of phenylacetylisoglutamine~~[, and the compound of Formula IV is the sodium salt of phenylacetate]~~.

20. (Previously Added) The method of claim 1, wherein said therapeutically-effective amount is from 20 mg/kg/day to 2500 mg/kg/day.

21. (Cancelled)